Phase 2 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People whose doctors estimate they are likely to survive for at least 3 months.
• People with multiple myeloma that has come back or stopped responding to treatment, or people with certain autoimmune or inflammatory conditions (such as lupus, inflammatory muscle disease, systemic sclerosis, IgG4-related disease, Sjögren's syndrome, rheumatoid arthritis, lung disease related to connective tissue conditions, immune thrombocytopenia, or primary biliary cholangitis) where standard treatments have not worked or no effective treatment is available.
• People with specific findings on a liver tissue sample showing a particular type of bile duct damage (confirm with trial site).
• People whose kidney function blood test result (creatinine) is within an acceptable range (no more than 1.5 times the upper limit of normal).
• People whose heart tracing (ECG) does not show any significant concerns.
• People whose blood oxygen level is above 91% without the use of supplemental oxygen.
• People whose liver function blood test results (bilirubin, ALT, and AST) fall within acceptable ranges, with some flexibility allowed for certain liver conditions or a diagnosed condition called Gilbert syndrome (confirm specific thresholds with trial site).
• People who do not have serious mental health disorders.
• People who are able to understand the trial and have signed a consent form agreeing to take part.

Who may not be able to join:

• People who have had a different type of cancer in the last 5 years, except for certain early-stage or fully treated cancers such as cervical carcinoma in situ, certain skin cancers, localised prostate cancer treated with surgery, or breast ductal carcinoma in situ treated with surgery.
• People who test positive for hepatitis B surface antigen, or who have certain hepatitis B antibody results combined with detectable hepatitis B virus in the blood, or who test positive for both hepatitis C antibody and hepatitis C virus in the blood, or who test positive for HIV, or who test positive for syphilis.
• People with serious heart conditions, including unstable chest pain, a heart attack or heart bypass or stent procedure within the past 6 months, significant heart failure, or severe irregular heart rhythms.
• People with unstable ongoing conditions affecting the liver, kidneys, or metabolism that require medication, as determined by the treating doctor.
• People who have an active or uncontrolled infection requiring treatment throughout the body in the 7 days before receiving the trial treatment (minor urinary or upper respiratory tract infections may be an exception — confirm with trial site).
• Women who are pregnant or breastfeeding, or women who plan to become pregnant within 2 years after receiving the cell treatment, or men whose partners plan to become pregnant within 2 years after the man receives the cell treatment.
• People who have previously received CAR-T cell therapy or any other type of gene-modified cell therapy.
• People who have taken part in another clinical trial in the month before screening for this trial.
• People who show signs that the disease has spread to the central nervous system (brain or spinal cord) at the time of screening.
• People who have depression or thoughts of suicide.
• People who the trial doctors consider unsuitable for the trial for any other reason.

Important: Always verify eligibility with the trial site directly before applying.